Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Jul 30, 2026 · Filed Jul 30, 2026
Cytokinetics's Chief Commercial Officer sold $1.12M of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,118,320
Shares × reported transaction price
86 days after results of May 5, 2026, 7 days before results of Aug 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.5% | +3.5% | −4.0% |
| 30 days | −8.1% | +2.7% | −10.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$265K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.